Evidence map›Paper›PMID 37142791›Full record

ArticleNature cell biology2023

SEL1L-HRD1 endoplasmic reticulum-associated degradation controls STING-mediated innate immunity by limiting the size of the activable STING pool.

Yewei Ji, Yuan Luo, Yating Wu, Yao Sun, Lianfeng Zhao, Zhen Xue, Mengqi Sun, Xiaoqiong Wei, Zinan He, Shuangcheng Alivia Wu and 14 more

Open access · hybridAbstract read
In one paragraph

Article in Nature cell biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
14.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Cell autonomous inflammation in VEXAS is mediated by cGAS-STING.bioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Targeting ubiquitination in disease and therapy.Signal transduction and targeted therapy · 2025
    Review
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 6 institutions in 2 countries.

Yewei Ji *Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. ywji@zju.edu.cn.ORCID http://orcid.org/0000-0003-4960-9928
Yuan Luo *Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yating WuZhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yao SunZhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Lianfeng ZhaoZhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhen XueGraduate Program in Nutrition, Cornell University, Ithaca, NY, USA.
Mengqi SunZhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiaoqiong WeiDepartment of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA.
Zinan HeZhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Shuangcheng Alivia WuDepartment of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA.
Liangguang Leo LinDepartment of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA.
You LuDepartment of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA.
Lei ChangZhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Fei ChenZhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Siyu ChenDepartment of Medical Microbiology and Parasitology, Zhejiang University School of Medicine, Hangzhou, China.
Wei QianDepartment of Immunology, School of Medicine, Jiangsu University, Zhenjiang, China.
Xiaoxi XuDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Shengnuo ChenZhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Dongli PanDepartment of Medical Microbiology and Parasitology, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0002-0421-6242
Zhangsen ZhouDepartment of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0001-7333-4624
Sheng XiaDepartment of Immunology, School of Medicine, Jiangsu University, Zhenjiang, China.
Chih-Chi Andrew HuCenter for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9024-2932
Tingbo LiangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0003-0143-3353
Ling QiDepartment of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA. lingq@med.umich.edu.ORCID http://orcid.org/0000-0001-8229-0184
First Affiliated Hospital Zhejiang University · CNUniversity of Michigan · USJiangsu University · CNCornell University · USHouston Methodist · USZhejiang University · CN

Funding

Pilot and Feasibility (P and F) ProgramP30DK089503 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Kanakadurga Singer · 2010 to 2026
$20.3M
Novel Role of Hepatic SEL1L-HRD1 ERAD in FGF21 Gene TranscriptionR01DK120330 · NIDDK · UNIVERSITY OF VIRGINIA · PI Deyu Fang, Ling Qi · 2018 to 2026
$4.9M
Targeting ER stress response in B-cell chronic lymphocytic leukemiaR01CA163910 · NCI · WISTAR INSTITUTE · PI Chih-Chi Andrew Hu · 2013 to 2026
$4.8M
Regulation of Mitochondrial Dynamics by ERAD: Administrative SupplementR35GM130292 · NIGMS · UNIVERSITY OF VIRGINIA · PI QI, LING · 2019 to 2023
$2.5M
Defining the Central Role of ER-Associated Degradation (ERAD) in Neuroendocrine CellsR01DK120047 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI QI, LING · 2018 to 2021
$1.6M
NCI NIH HHS R01 CA163910NIDDK NIH HHS P30 DK089503NIDDK NIH HHS R01 DK120047NIDDK NIH HHS R01 DK120330NIGMS NIH HHS R35 GM130292
6 · The paper itself

Abstract

Stimulator of interferon genes (STING) orchestrates the production of proinflammatory cytokines in response to cytosolic double-stranded DNA; however, the pathophysiological significance and molecular mechanism underlying the folding and maturation of nascent STING protein at the endoplasmic reticulum (ER) remain unknown. Here we report that the SEL1L-HRD1 protein complex-the most conserved branch of ER-associated degradation (ERAD)-is a negative regulator of the STING innate immunity by ubiquitinating and targeting nascent STING protein for proteasomal degradation in the basal state. SEL1L or HRD1 deficiency in macrophages specifically amplifies STING signalling and immunity against viral infection and tumour growth. Mechanistically, nascent STING protein is a bona fide substrate of SEL1L-HRD1 in the basal state, uncoupled from ER stress or its sensor inositol-requiring enzyme 1α. Hence, our study not only establishes a key role of SEL1L-HRD1 ERAD in innate immunity by limiting the size of the activable STING pool, but identifies a regulatory mechanism and therapeutic approach to targeting STING.

Indexed as

Endoplasmic Reticulum-Associated DegradationUbiquitin-Protein LigasesEndoplasmic ReticulumImmunity, InnateProteinsProteinsUbiquitin-Protein Ligases

Identifiers

PMID37142791
PMCPMC10185471
OpenAlexW4372334035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.